On a roll, Macro­Gen­ics al­lies with Roche on a bis­pe­cif­ic de­vel­op­ment cam­paign

Just weeks af­ter sign­ing a $900 mil­lion pact with In­cyte for its ear­ly-stage PD-1 check­point, Macro­Gen­ics $MGNX is back with a new deal cov­er­ing the de­vel­op­ment of bis­pecifics for a va­ri­ety of dis­eases for Roche. Roche $RHH­BY, which just bought out Igny­ta for $1.7 bil­lion, is pay­ing a mod­est $10 mil­lion up­front for the pact and com­mit­ting to up to $370 mil­lion in mile­stones.

The col­lab­o­ra­tion brings to­geth­er the biotech’s DART plat­form and Roche’s Cross­MAb and DutaFab tech­nolo­gies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER